Werewolf Therapeutics (NASDAQ:HOWL), an innovative biopharmaceutical company developing "inducible" cytokines to treat cancer, today announced it has initiated a formal process to explore strategic alternatives.
The company has engaged Piper Sandler as its exclusive financial advisor to evaluate a range of options, including a potential sale, merger, divestiture of assets, or proprietary licensing agreements.
The strategic review follows a period of significant operational discipline.
For the full year ended December 31, 2025, Werewolf reported a net loss of $60.8 million, an improvement from the $72.4 million loss in 2024.
The company successfully reduced its research and development (R&D) expenses to $44.8 million—down from $54.1 million—while maintaining General and Administrative (G&A) spending at $15.8 million.
These cost-saving measures were part of a broader effort to preserve capital while advancing its PREDATOR™ platform.
As of December 31, 2025, Werewolf held cash and cash equivalents of $57.1 million.
Based on its current operating plan, the company expects its existing liquidity to fund operations into the fourth quarter of 2026.
This limited runway appears to be a primary driver for the current strategic pivot, as the company seeks a partner or acquirer with the capital necessary to advance its lead programs, WTX-124 (IL-2) and WTX-330 (IL-12), into late-stage clinical trials.
The company's PREDATOR™ technology remains its most valuable asset.
The platform creates "conditionally active" cytokines that are designed to remain inactive (or "masked") while in systemic circulation, only becoming fully potent once they reach the tumor microenvironment.
This approach aims to solve the historic toxicity issues associated with traditional cytokine therapies, a challenge that has recently renewed interest from "Big Pharma" oncology departments looking for the next generation of immuno-oncology (IO) agents.